BioNxt Solutions Inc. (CVE:BNXT) | Finanzwire

Basculer en Français

11212	Companies
248498	Keywords
176260	Articles
134386	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 10/19/2026 at 09:10, 2 days 18 hours ago

BioNxt Solutions Advances with GMP Manufacturing and Clinical Trial Application

Clinical Trial Multiple Sclerosis Cladribine GMP Manufacturing BioNxt Solutions
PRESS RELEASE

published on 10/19/2026 at 09:05, 2 days 19 hours ago

BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
BioNxt Solutions Inc. announces GMP manufacturing of Cladribine films & European CTA submission for MS drug candidate BNT23001, advancing toward human clinical study and comparative bioequivalence evaluation

BioNxt Solutions Inc. GMP Manufacturing BNT23001 Cladribine Films MS Drug Candidate
BRIEF

published on 09/08/2026 at 09:10, 1 month 13 days ago

BioNxt Advances Everolimus ODF with Animal Study

Pharmacokinetic Study Drug Delivery BioNxt Solutions Organ Transplantation Everolimus ODF
PRESS RELEASE

published on 09/08/2026 at 09:05, 1 month 13 days ago

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
BioNxt Solutions Inc. announces the advancement of its sublingual Everolimus oral dissolvable film program targeting organ transplantation, with a comparative pharmacokinetic study

BioNxt Solutions Inc. Pharmacokinetic Study Sublingual Organ Transplantation Everolimus
BRIEF

published on 08/26/2026 at 09:10, 1 month 26 days ago

BioNxt Completes IMPD for Multiple Sclerosis Drug Program

Multiple Sclerosis Drug Delivery BioNxt Solutions Cladribine ODF IMPD Completion
PRESS RELEASE

published on 08/26/2026 at 09:05, 1 month 26 days ago

BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
BioNxt Solutions Inc. announces completion of the Investigational Medicinal Product Dossier (IMPD) for BNT23001, their proprietary sublingual cladribine oral dissolvable film product for multiple sclerosis. Key regulatory milestone achieved

BioNxt Solutions Inc. Multiple Sclerosis BNT23001 Investigational Medicinal Product Dossier IMPD
BRIEF

published on 08/22/2026 at 00:35, 2 months ago

BioNxt Solutions Inc. Completes Convertible Debentures Extension and Warrant Issuance

Convertible Debentures Maturity Extension Securities Legislation BioNxt Solutions Warrant Issuance
PRESS RELEASE

published on 08/22/2026 at 00:30, 2 months ago

BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
BioNxt Solutions Inc. announces the extension of unsecured convertible debentures with amended terms and issuance of common share purchase warrants

Warrants BioNxt Solutions Inc. BioScience Debentures Convertible
BRIEF

published on 08/19/2026 at 09:10, 2 months 2 days ago

BioNxt Completes IMPD for Multiple Sclerosis Treatment

Clinical Trials Multiple Sclerosis BioNxt Solutions Drug Delivery Systems IMPD Completion
PRESS RELEASE

published on 08/19/2026 at 09:05, 2 months 2 days ago

BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
BioNxt Solutions Inc. completes Investigational Medicinal Product Dossier (IMPD) for BNT23001, a sublingual cladribine oral dissolvable film for multiple sclerosis. IMPD is a significant regulatory milestone for the Company's lead drug candidate

BioNxt Solutions Inc. Sublingual Cladribine BNT23001 Investigational Medicinal Product Dossier IMPD

Accesswire

Published on 10/21/2026 at 22:00, 6 hours 5 minutes ago

Prospect Ridge Announces Second Tranche Closing of Critical Metals Flow-Through Unit Private Placement
Published on 10/21/2026 at 15:00, 13 hours 5 minutes ago

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Published on 10/21/2026 at 14:40, 13 hours 25 minutes ago

Axo Metals Receives Approval to Trade on the OTCQB Venture Market Under the Symbol AXOCF
Published on 10/21/2026 at 14:30, 13 hours 35 minutes ago

Fermi Provides Letter to Shareholders from CEO Lee McIntire on Financing Fermi's Next Chapter
Published on 10/21/2026 at 14:00, 14 hours 5 minutes ago

Nine Mile Metals DDH WD-26-18 Intersects A High Grade VMS Lens, Returning 7.13% Cu-Eq Over 11.65 M Including 9.93% Cu-Eq Over 6.70 M And 10.46% Cu-Eq Over 4.80 M, With An Additional Upper 31.50m Copper Stringer Zone

View all ACCESSWIRE

EQS Group

Published on 10/22/2026 at 00:00, 4 hours 4 minutes ago

EQS-Adhoc: Marley Spoon Group SE: Extension and increase of restructuring bridge financing for Marley Spoon SE
Published on 10/21/2026 at 23:38, 4 hours 27 minutes ago

QIAGEN und EQT Private Equity geben Einigung über ein empfohlenes freiwilliges öffentliches Übernahmeangebot in bar bekannt
Published on 10/21/2026 at 23:32, 4 hours 33 minutes ago

EQS-Adhoc: QIAGEN N.V.: Conclusion of a Business Combination Agreement with EQT Private Equity; preliminary Q3 2026 results and suspension of full-year 2026 outlook
Published on 10/21/2026 at 23:30, 4 hours 35 minutes ago

EQS-WpÜG: Takeover Offer / Target company: Qiagen N.V.; Bidder: Crown NL Bidco B.V.
Published on 10/21/2026 at 19:35, 8 hours 29 minutes ago

Leifheit Aktiengesellschaft: Leifheit revises its forecast for 2026 and accelerates the consistent implementation of the FOCUS performance program

Les Echos

Published on 10/21/2026 at 18:00, 10 hours 5 minutes ago

Saint-Gobain accelerates its growth in Egypt with the opening of two new production capacities
Published on 10/21/2026 at 17:59, 10 hours 6 minutes ago

Covivio Hotels : Revenues up +4.7% at end-September 2026
Published on 10/21/2026 at 17:45, 10 hours 20 minutes ago

Covivio - Q3 2026 activity : Accelerating organic revenue growth supported by strong operational execution
Published on 10/21/2026 at 17:40, 10 hours 25 minutes ago

Eiffage has signed a memorandum of understanding with the LOSC regarding the proposed disposal of the companies in charge of the management of the Decathlon Arena - Stade Pierre-Mauroy and its ancillary areas
Published on 10/21/2026 at 17:39, 10 hours 26 minutes ago

Solocal - Q3 2026 Revenue and Activity

View all LES ECHOS COMFI WIRE